Edaravone Pharmaceutical Market in China 2021
The edaravone pharmaceutical market in China in terms of revenue is expected to decline at a compound annual growth rate (CAGR) of -0.8% from US$ 426 million in 2020 to 429 million in 2027, according to data and analytics company StrategyHelix.
The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for edaravone pharmaceutical. The China edaravone pharmaceutical market is segmented on the basis of region. By region, it is categorized into Central South China, East China, North China, Northeast China, Northwest China, and Southwest China.
The report has profiled some of the key players of the market such as China National Pharmaceutical Group Corp., Fujian Tianquan Pharmaceutical Co. Ltd., Jilin Boda Pharmaceutical Co. Ltd., Simcere Pharmaceutical Group Limited, Yangzijiang Pharmaceutical Group Nanjing Hailing Pharmaceutical Co. Ltd..
The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the edaravone pharmaceutical market to help drive informed decision making for industry executives, policy makers, academic, and analysts.
Report Scope
Region: Central South China, East China, North China, Northeast China, Northwest China, and Southwest China
Years Considered: this report covers the period 2017 to 2027
Key Benefits for Stakeholders
Get a comprehensive picture of the China edaravone pharmaceutical market
Pinpoint growth sectors and trends for investment
Understand what the future of the edaravone pharmaceutical market in China looks like
Identify the competitive landscape and window of opportunity
The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for edaravone pharmaceutical. The China edaravone pharmaceutical market is segmented on the basis of region. By region, it is categorized into Central South China, East China, North China, Northeast China, Northwest China, and Southwest China.
The report has profiled some of the key players of the market such as China National Pharmaceutical Group Corp., Fujian Tianquan Pharmaceutical Co. Ltd., Jilin Boda Pharmaceutical Co. Ltd., Simcere Pharmaceutical Group Limited, Yangzijiang Pharmaceutical Group Nanjing Hailing Pharmaceutical Co. Ltd..
The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the edaravone pharmaceutical market to help drive informed decision making for industry executives, policy makers, academic, and analysts.
Report Scope
Region: Central South China, East China, North China, Northeast China, Northwest China, and Southwest China
Years Considered: this report covers the period 2017 to 2027
Key Benefits for Stakeholders
Get a comprehensive picture of the China edaravone pharmaceutical market
Pinpoint growth sectors and trends for investment
Understand what the future of the edaravone pharmaceutical market in China looks like
Identify the competitive landscape and window of opportunity
1. MARKET DEFINITION
2. RESEARCH METHODOLOGY
3. MARKET DATA & OUTLOOK
3.1 Market Value
3.2 Market Value Forecast
4. EDARAVONE PHARMACEUTICAL MARKET BY REGION
4.1 Central South China
4.2 East China
4.3 North China
4.4 Northeast China
4.5 Northwest China
4.6 Southwest China
5. COMPANY PROFILES
5.1 China National Pharmaceutical Group Corp.
5.2 Fujian Tianquan Pharmaceutical Co., Ltd.
5.3 Jilin Boda Pharmaceutical Co., Ltd.
5.4 Simcere Pharmaceutical Group Limited
5.5 Yangzijiang Pharmaceutical Group Nanjing Hailing Pharmaceutical Co., Ltd.
6. APPENDIX
6.1 About StrategyHelix
6.2 Disclaimer
2. RESEARCH METHODOLOGY
3. MARKET DATA & OUTLOOK
3.1 Market Value
3.2 Market Value Forecast
4. EDARAVONE PHARMACEUTICAL MARKET BY REGION
4.1 Central South China
4.2 East China
4.3 North China
4.4 Northeast China
4.5 Northwest China
4.6 Southwest China
5. COMPANY PROFILES
5.1 China National Pharmaceutical Group Corp.
5.2 Fujian Tianquan Pharmaceutical Co., Ltd.
5.3 Jilin Boda Pharmaceutical Co., Ltd.
5.4 Simcere Pharmaceutical Group Limited
5.5 Yangzijiang Pharmaceutical Group Nanjing Hailing Pharmaceutical Co., Ltd.
6. APPENDIX
6.1 About StrategyHelix
6.2 Disclaimer
